Authors of a recent randomized study sought to determine the relative risks and benefits of continuing dual antiplatelet therapy (DAPT) beyond one year after coronary drug-eluting stent (DES) placement. According to the study, which of the following statements is most likely true regarding patients whose DAPT was continued beyond one year?

DAPT is recommended after implantation of cardiac DES to prevent in-stent thrombosis. Current guidelines from the American Heart Association/American College of Cardiology and European Society of Cardiology recommend continuation of DAPT for at least 12 months in the absence of major bleeding complications. Whether continuing DAPT beyond 12 months is beneficial remains controversial.

An extension to the 2011 ARCTIC-Monitoring* trial was recently conducted to determine whether continuation of DAPT beyond 12 months was beneficial. In the original ARCTIC trial, 2,440 patients scheduled for elective DES implantation were randomized...

You do not currently have access to this content.